ICU - Eying long position
Seastar Medical, operating within the rapidly growing biotechnology sector projected to reach $3879.51 billion by 2030, is at the forefront with its Selective Cytopheretic Device (SCD) aimed at treating excessive inflammation through extracorporeal therapies. Despite a significant financial downtur